Fludrocortisone Therapy in Renal Transplant Recipients with Persistent Hyperkalemia

License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Hyperkalemia after kidney transplantation is a common electrolyte disturbance and the risk factors are multifactorial. Pharma-cotherapeutic agents for chronic management of hyperkalemia in kidney transplant patients may be relatively contraindicated or provide suboptimal efficacy. Fludrocortisone, an endogenous mineralocorticoid mimics the actions of aldosterone, hence hyperkalemia reversal. We describe three- case series of persistent hyperkalemia with demonstrated benefit from fludrocortisone therapy. Our three renal transplant recipients with multiple emergency room visits for elevated serum potassium levels despite treatment with diuretics, sodium bicarbonate, and sodium polystyrene sulfonate responded well to fludrocortisones therapy. Upon fludrocortisone initiation and maintenance therapy, all three patients experienced a decline in serum potassium levels to normal reference range. 1